Clinical trials: Anticoagulant
Atrial Fibrillation, Anticoagulant Adverse Reaction
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
- Trial name
- REVISE-AF (NCT06187311)
- Testing
- Rivaroxaban 20 MG, Rivaroxaban 15 MG
- Where
- South Korea
- Volunteers
- 940 people
- Sponsor
- Korea University Anam Hospital
Acute Myocardial Infarction, Left Ventricular Thrombosis
Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
Patients with acute ST-segment elevation myocardial infarction (STEMI) have an elevated risk of stroke, most of which are cardio-embolic in origin as a result of left ventricular (LV) thrombus formation.
- Conditions
- Acute Myocardial Infarction, Left Ventricular Thrombosis, Anticoagulants and Bleeding Disorders
- Trial name
- NCT03232398
- Testing
- Apixaban Oral Tablet [Eliquis], Warfarin
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Hadassah Medical Organization
Intracerebral Hemorrhage, Intracerebral Haemorrhage
International Care Bundle Evaluation in Cerebral Hemorrhage Research
Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality.
- Conditions
- Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke
- Trial name
- I-CATCHER (NCT06429332)
- Testing
- Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 3,500 people
- Sponsor
- Region Skane
Anticoagulant Reversal
Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin
The purpose of this research study is to see how well an experimental freeze dried plasma product, known as FDP, works to reverse the anticoagulation effects of a prescription medication called warfarin sodium (warfarin) compared…
- Trial name
- NCT04794348
- Testing
- Fresh Frozen Plasma (FFP), Freeze Dried Plasma (FDP)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Teleflex
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Healthy Volunteers
Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
The primary objective of the trial is to investigate the pharmacokinetics and pharmacodynamics of idarucizumab in Chinese healthy male and female subjects following intravenous administration of idarucizumab followed by…
- Trial name
- NCT03086356
- Testing
- Dabigatran etexilate, Idarucizumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Embolism, Thrombosis
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary…
- Trial name
- CASSIOPEA (NCT00345618)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 3,202 people
- Sponsor
- Sanofi
Venous Thromboembolism
Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
Study will assess PK/PD parameters and safety and tolerability of the study medication in this age group
- Trial name
- NCT01773174
- Testing
- dabigatran etexilate
- Where
- 8 sites in United States
- Sponsor
- Boehringer Ingelheim
Thromboembolic Disease
Safety of Direct Oral Anticoagulant During Pregnancy
Pregnancy is a major risk factor of thromboembolic disease (2 to 10 increased risk of thromboembolic event for pregnant women). This risk is related to the physiological changes inducing venous stasis and hypercoagulability.
- Trial name
- SACOD (NCT06179823)
- Where
- France
- Volunteers
- 1,755,558 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Pulmonary Embolism
Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.
Rational: After 3 or 6 months of oral anticoagulation for an episode of acute venous thromboembolism (VTE), the risk of recurrent VTE is high (10 to 15% per year) in comparison with a low risk of recurrence if VTE was provoked by…
- Trial name
- PADIS EP (NCT00740883)
- Testing
- warfarin
- Where
- France
- Volunteers
- 374 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Stroke, Ischemic
Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial
The overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to…
- Trial name
- STROKE75+ (NCT07454707)
- Testing
- Edoxaban 15 mg, Aspirin or clopidogrel
- Where
- Canada
- Volunteers
- 1,204 people
- Sponsor
- Sunnybrook Health Sciences Centre
Coagulation Disorder
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
A single centre, open-label study to assess the effects of VMX-C001 in combination with an oral FXa DOAC on the efficacy of Unfractionated Heparin (UFH) and of VMX-C001 alone on the efficacy of Low Molecular Weight Heparin (LMWH)…
- Trial name
- NCT06517563
- Testing
- VMX-C001, Rivaroxaban, UFH
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE), Prevention
- Trial name
- NCT07124819
- Testing
- Sodium enoxaparin, Dimolegin
- Where
- 8 sites in Russia
- Volunteers
- 215 people
- Sponsor
- Avexima Diol LLC
Anticoagulants and Bleeding Disorders
Evaluating LumiraDx INR Test Accuracy in Patients Taking Phenprocoumon Anticoagulant.
This study is to evaluate the INR levels in patients taking phenprocoumon using the LumiraDx Point of Care INR test and comparing the results to the laboratory reference method , the ACL Elite Pro.
- Trial name
- VKA_GERMANY (NCT04074980)
- Testing
- Venous and Fingerstick blood draws, Venous blood draw
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- LumiraDx UK Limited
Patent Foramen Ovale
Anticoagulants for PFO Patients
Patients who underwent both bubble transcranial Doppler (bubble-TCD) and transoesophageal echocardiography (TEE) at our institution were consecutively enrolled in this real-world case-control study from August 2016 through August…
- Trial name
- NCT06375070
- Testing
- PFO closure, anticoagulant
- Volunteers
- 277 people
- Sponsor
- Xuanwu Hospital, Beijing
Severe Trauma Patient, Venous Thromboembolism
Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial
Venous thromboembolism is a frequent issue in severe trauma patients. Guidelines for venous thromboembolism prevention include the use of pharmacological thromboprophylaxis, mainly with low-molecular-weight heparin, and/or…
- Trial name
- HEPTRAUMA (NCT07506473)
- Testing
- Enoxaparin standard dose, Enoxaparin intermediate dose
- Where
- 17 sites in France
- Volunteers
- 540 people
- Sponsor
- University Hospital, Grenoble
Cerebral Hemorrhage, Intracranial Hemorrhages
Study of Antithrombotic Treatment After IntraCerebral Haemorrhage
The study evaluates the effects of antithrombotic drugs (anticoagulant drugs or antiplatelet drugs) for prevention of ischaemic events in patients With recent intracerebral haemorrhage.
- Conditions
- Cerebral Hemorrhage, Intracranial Hemorrhages, Atrial Fibrillation, Anticoagulant-Induced Bleeding
- Trial name
- STATICH (NCT03186729)
- Testing
- Antithrombotic Agent
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 134 people
- Sponsor
- Oslo University Hospital
Post Operative Hemorrhage
Direct Oral Anticoagulants and Management of Blleding Following Dental Extractions. A Prospective Cohort Study.
Evaluation of DOACs treatment on post-extraction bleeding
- Trial name
- DOACS_1 (NCT06365242)
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- University of Pisa